Navigation Links
Selexis SA to Present at Cell Line Development and Engineering 2013

Geneva, Switzerland (PRWEB) February 07, 2013

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the Company’s co-founder will present data on the Company’s core technology at the Cell Line Development and Engineering 2013 conference being held February 11 – 15 in Vienna, Austria. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression,” on Friday, February 15 at 1:45 PM as part of the CHO Cell Engineering tract.

Presentation Abstract
“Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression”
Incorporation of epigenetic regulatory DNA elements to prevent silencing can yield high and stable expression from CHO cells with a high frequency. We determined the sequence of a CHO genome used for pharmaceutical production and of derived therapeutic producing clones and allowed the characterisation of the alterations of the genomic and transgene sequence of candidate cell lines. This presentation will illustrate how a systematic and multi-level ‘Omics’ approach may be used to improve the expression of pharmaceutical proteins.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and morestable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
(Date:10/7/2015)... , Oct. 7, 2015   PDI , ... released an infographic that highlights key challenges across various ... appropriate disinfectant for the situation. This tool is part ... hospitals can take to create efficiencies and lower healthcare-associated ... The visual guide emphasizes examples of how to use ...
(Date:10/7/2015)...   VWR (NASDAQ: VWR ), ... services and solutions, announced today that it has ... company that performs high volume purification of selected ... growing laboratory and production chemical manufacturing portfolio to ... Manuel Brocke-Benz , President and CEO ...
(Date:10/7/2015)... ... 07, 2015 , ... Park Systems , world-leader in ... provide a comprehensive overview of the innovations in smart coatings using nanoparticle additives ... This webinar will be given by Professor Roberto Advincula, professor with the Department ...
Breaking Biology Technology:
... Green Mountain Energy Company to take the necessary steps in ... enabling them to operate as a "carbon neutral" analytical laboratory. ... ... Alkemists Pharmaceuticals today announced that it has partnered with Green Mountain ...
... 30 , - Shares Acquired From Biggar ... biotechnology company,focused on eye disease, vascular disease and ... based in Belgium have together acquired an 8%,stake ... Biggar Limited, a,charitable foundation that is ThromboGenics largest ...
... SAN DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... second quarter 2008,financial results after the NASDAQ Global ... afternoon, Jack Lief, Arena,s President and Chief,Executive Officer, ... Chief Financial Officer, will host a conference call ...
Cached Biology Technology:
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):
... began a rapid period of change called the Cambrian ... life forms over many millions of years that ultimately ... help palaeontologists chronicle the evolution of life since then, ... billion years that preceded the Cambrian Period is challenging, ...
... turnover and remodelling of lipid membranes could help phytoplankton cope ... team led by Patrick Martin of the National Oceanography Centre ... rapidly change the chemical composition of its cell membranes in ... the process may be important for nutrient cycling and the ...
... University researchers focusing on rice genetics are providing a ... nutrients. Their research provides insight into ways of ... research. Frank White, professor of plant pathology, and ... in partnership with researchers at three other institutions, of ...
Cached Biology News: